Acute Lymphoblastic Leukemia (ALL) Cell Models for Research

Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy, accounting for approximately 25% of childhood cancers. According to the World Health Organization (WHO), the global incidence of ALL is estimated at 1-4.75 per 100,000 individuals per year, with a peak incidence between ages 2 and 5. In the United States, the National Cancer Institute (NCI) reports an estimated 6,540 new cases and 1,390 deaths in 2023. The 5-year survival rate for children under 15 has improved dramatically to over 90%, but for adults, the prognosis remains poorer, with a 5-year survival of only 30-40%. Key risk factors include genetic syndromes (e.g., Down syndrome), exposure to ionizing radiation, and certain chemotherapy agents. Despite advances, relapse and refractory disease remain major challenges, emphasizing the need for novel therapeutic targets and models.

ALL is an ideal model for mechanistic studies due to its well-defined genetic subtypes, availability of numerous cell lines, and extensive public datasets. The disease is characterized by recurrent chromosomal translocations, such as t(12;21) (ETV6-RUNX1), t(9;22) (BCR-ABL1), and rearrangements of MLL (KMT2A), which provide clear genetic drivers. Additionally, large-scale genomic efforts like The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have cataloged somatic mutations, copy number alterations, and gene expression profiles. Open questions include the role of epigenetic dysregulation, the tumor microenvironment, and mechanisms of drug resistance. Gene-edited cell models enable functional validation of these alterations, facilitating target identification and drug development.

The pathogenesis of ALL involves several key pathways:

• • Cell cycle regulation: Dysregulation of CDKN2A/B (p16/p15) leads to uncontrolled proliferation. Loss of p53 function impairs apoptosis.
• • Lymphoid differentiation: Blockade of B-cell or T-cell differentiation due to transcription factor alterations (e.g., PAX5, IKZF1) results in accumulation of immature blasts.
• • Kinase signaling: Constitutive activation of tyrosine kinases (e.g., ABL1, JAK2) drives proliferation and survival.
• • Epigenetic modifiers: Mutations in genes such as DNMT3A, TET2, and EZH2 alter DNA methylation and histone modifications, contributing to leukemogenesis.

Data compiled from TCGA and COSMIC.

Key signaling networks in ALL include:

• • PI3K/AKT/mTOR pathway: Often activated by mutations in PTEN or upstream receptors, promoting cell survival and proliferation.
• • JAK-STAT pathway: Constitutive activation via JAK2 mutations or cytokine receptor overexpression leads to uncontrolled growth.
• • RAS/MAPK pathway: Mutations in NRAS, KRAS, or PTPN11 result in sustained proliferative signaling.
• • NOTCH signaling: Particularly in T-ALL, activating mutations in NOTCH1 drive leukemogenesis.
• • Wnt/β-catenin pathway: Aberrant activation contributes to self-renewal and therapy resistance.

Commonly used ALL cell lines include:

Organoid models are emerging as more physiologically relevant systems, preserving 3D architecture and cell-cell interactions, but are less established for ALL compared to solid tumors.

Animal models are essential for studying ALL in vivo:

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient leukemia cells; preserve genetic heterogeneity and drug response.
• • Genetically engineered mouse models (GEMM): Transgenic or knockout mice that develop ALL, such as BCR-ABL1 transgenic or NOTCH1 knock-in models.
• • Induced models: Use of chemical carcinogens or viral vectors to induce leukemia, though less specific.

These models are used for preclinical drug testing and mechanistic studies.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models. By introducing specific knockouts, knock-ins, or point mutations into ALL cell lines, researchers can precisely study the impact of genetic alterations. For example:

• • CDKN2A knockout NALM6 cells: Used to study cell cycle dysregulation.
• • BCR-ABL1 knock-in SUP-B15 cells: Model chronic myeloid leukemia blast crisis and test tyrosine kinase inhibitors.
• • NOTCH1 mutant JURKAT cells: Investigate NOTCH signaling in T-ALL.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and validated models, eliminating the time-consuming process of generating and validating edits in-house. These models are essential for drug discovery, target validation, and functional genomics.

Gene-edited cells are used to validate the functional role of genes in ALL. For example:

• • Knockout of tumor suppressors (e.g., TP53, PTEN) confirms their role in apoptosis and proliferation.
• • Knock-in of oncogenic mutations (e.g., BCR-ABL1, NOTCH1) demonstrates their transforming potential.
• • CRISPR screens in isogenic backgrounds can identify synthetic lethal partners and essential genes.

These approaches help prioritize therapeutic targets.

Isogenic cell line pairs (wild-type vs. gene-edited) are powerful tools for drug screening:

• • Screening: Compare drug sensitivity between isogenic lines to identify genotype-specific responses.
• • Resistance: Generate resistant lines by chronic drug exposure or by introducing resistance mutations (e.g., BCR-ABL1 T315I) to study mechanisms and develop next-generation inhibitors.
• • Combination therapy: Test synergistic effects of drugs using isogenic lines with defined genetic backgrounds.

CRISPR-based synthetic lethality screens can identify biomarkers that predict drug response. For example:

• • Screens in isogenic lines with specific mutations can reveal genes whose loss sensitizes cells to particular drugs.
• • Gene expression profiling of edited lines can uncover downstream effectors and potential biomarkers.
• • Functional validation of candidate biomarkers in patient samples can be accelerated using edited cell models.